- Home
- COE vs ECOR Comparison
COE vs ECOR Comparison
Compare COE & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COE
- ECOR
- Stock Information
- Founded
- COE 2011
- ECOR 2005
- Country
- COE Singapore
- ECOR United States
- Employees
- COE N/A
- ECOR N/A
- Industry
- COE Other Consumer Services
- ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- COE Real Estate
- ECOR Health Care
- Exchange
- COE Nasdaq
- ECOR Nasdaq
- Market Cap
- COE 102.9M
- ECOR 111.3M
- IPO Year
- COE 2016
- ECOR 2018
- Fundamental
- Price
- COE $20.10
- ECOR $15.90
- Analyst Decision
- COE
- ECOR Strong Buy
- Analyst Count
- COE 0
- ECOR 1
- Target Price
- COE N/A
- ECOR $25.00
- AVG Volume (30 Days)
- COE 25.2K
- ECOR 144.8K
- Earning Date
- COE 12-13-2024
- ECOR 03-12-2025
- Dividend Yield
- COE N/A
- ECOR N/A
- EPS Growth
- COE N/A
- ECOR N/A
- EPS
- COE N/A
- ECOR N/A
- Revenue
- COE $41,924,000.00
- ECOR $23,327,000.00
- Revenue This Year
- COE N/A
- ECOR $59.81
- Revenue Next Year
- COE N/A
- ECOR $38.49
- P/E Ratio
- COE N/A
- ECOR N/A
- Revenue Growth
- COE 69.79
- ECOR 74.10
- 52 Week Low
- COE $6.00
- ECOR $5.32
- 52 Week High
- COE $21.97
- ECOR $18.67
- Technical
- Relative Strength Index (RSI)
- COE 65.30
- ECOR 53.73
- Support Level
- COE $19.13
- ECOR $15.50
- Resistance Level
- COE $21.97
- ECOR $16.12
- Average True Range (ATR)
- COE 1.44
- ECOR 1.20
- MACD
- COE -0.06
- ECOR -0.31
- Stochastic Oscillator
- COE 67.26
- ECOR 40.17
About COE 51Talk Online Education Group
51 Talk Online Education Group is an online education platform in China, with core expertise in English education. The company's mission is to make quality education accessible and affordable. It's online and mobile education platforms enable students across China to take live interactive English lessons with overseas foreign teachers, on demand.
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.